pharmaphorum7d
COPD triple approved, can GSK maximise its revenues?
Approved yesterday by the FDA, Trelegy Ellipta is the first ever daily single-inhaler to combine a triple therapy for COPD, and could ... as the first Advair generic looks to be just around ...
Healthy Returns: Drugmakers are capping inhaler prices at $35 in a win for some patients
Generic inhalers can cost as little as $30 ... cap applies to both of those products and the rest of its asthma and COPD ...
Monthly Prescribing Reference14d
Study Compares Single-Inhaler Triple Therapies for Treatment of COPD
Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...
thecardiologyadvisor.com5d
In COPD, CV Events Increase With Use of Single-Inhaler Triple Therapy
Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.
pharmaphorum4y
Teva launches digital asthma and COPD rescue inhaler in US
Teva has launched new digital inhaler ... generic version of GlaxoSmithKline’s blockbuster inhaler Advair (fluticasone+salmeterol). The competition for the product approved in asthma and COPD ...
2minutemedicine.com12d
Different single inhaler triple therapies appear to have similar clinical outcomes for chronic obstructive pulmonary disease
In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...
FTC opens investigation into Teva, escalating patent fight with pharma industry
The Federal Trade Commission has opened an investigation into Teva Pharmaceuticals, citing the company’s refusal to take down ...